Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis

We aimed to provide a quantitative description of decay in pertussis antibody levels to aid in finding a serological estimate of the incidence of pertussis. The serum IgG response against pertussis toxin was studied in a group of clinically diagnosed patients. Individual records consisted of repeated serum IgG measurements at irregular intervals for up to 10 years post diagnosis. These data were analysed with a nonlinear regression model taking into account censoring at upper and lower threshold levels, measurement errors, and individual variation in the shape and magnitude of the immune response. There was considerable variation between individual responses, both in strength (amplitude) and duration (shape). The inverse model relating IgG levels to time from infection (diagnosis) can be applied to cross-sectional IgG data to generate distributions of times from infection, which may be used to calculate infection rates and their variation, in populations sampled for cross-sectional IgG data.

[1]  M. Brennan,et al.  Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  H. Hallander,et al.  Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. , 2000, Vaccine.

[3]  A. Wardlaw,et al.  Time-course of infection and responses in a coughing rat model of pertussis. , 1999, Journal of medical microbiology.

[4]  T. Kurashige,et al.  Immune responses to Bordetella pertussis infection and vaccination. , 1991, The Journal of infectious diseases.

[5]  W. Slob,et al.  Analysis of Variable Fractions Resulting from Microbial Counts , 1999 .

[6]  H. Melker,et al.  Seroepidemiology of diphtheria, tetanus, poliomyelitis and pertussis : evaluation of the national immunisation programme in the Netherlands , 1999 .

[7]  J. Taranger,et al.  Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. , 1995, Scandinavian journal of infectious diseases.

[8]  C. Y. Lee,et al.  Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age. , 1996, Vaccine.

[9]  S. de Graaf,et al.  Improved serodiagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels. , 1985, Developments in biological standardization.

[10]  J. Roord,et al.  Laboratory‐confirmed reinfections with Bordetella pertussis , 2002, Acta paediatrica.

[11]  F. Mooi,et al.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. , 2000, Emerging infectious diseases.

[12]  E. Arjas,et al.  A Hierarchical Bayesian Model to Predict the Duration of Immunity to Haemophilus Influenzas Type B , 1999, Biometrics.

[13]  P Van Damme,et al.  Inactivated hepatitis A vaccine‐induced antibodies: Follow‐up and estimates of long‐term persistence , 2001, Journal of medical virology.

[14]  S. Salmaso,et al.  Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. , 1998, The Journal of pediatrics.

[15]  R. Rappuoli,et al.  Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. , 1997, Vaccine.

[16]  A. Finn,et al.  Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. , 1996, Archives of disease in childhood.

[17]  Back-calculating the age-specific incidence of recurrent subclinical Haemophilus influenzae type b infection. , 2000, Statistics in medicine.

[18]  K. Edwards,et al.  Natural history of pertussis antibody in the infant and effect on vaccine response. , 1990, The Journal of infectious diseases.

[19]  J. Schellekens,et al.  Specificity and Sensitivity of High Levels of Immunoglobulin G Antibodies against Pertussis Toxin in a Single Serum Sample for Diagnosis of Infection with Bordetella pertussis , 2000, Journal of Clinical Microbiology.

[20]  Peter Green,et al.  Markov chain Monte Carlo in Practice , 1996 .

[21]  P. Mastrantonio,et al.  Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. , 1997, Developments in biological standardization.

[22]  P. Beutels,et al.  Mathematical models for assessment of long‐term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines , 2000, Journal of medical virology.

[23]  N. Gay.  Analysis of serological surveys using mixture models: application to a survey of parvovirus B19. , 1996, Statistics in medicine.

[24]  T. Kurashige,et al.  The longevity of the immune response to filamentous hemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community. , 1992, The Journal of infectious diseases.